Skip to main content
. Author manuscript; available in PMC: 2011 Apr 29.
Published in final edited form as: Vaccine. 2011 Feb 22;29(15):2705–2711. doi: 10.1016/j.vaccine.2011.01.079

Fig. 2.

Fig. 2

The indicated dilutions of sera from six CMV seropositive and two CMV seronegative human subjects, postimmune rabbit anti-peptide sera, and corresponding preimmune rabbit sera were incubated with 4000 pfu of virus BADrUL131-Y4 for 1 h, then used to infect ARPE-19 epithelial cells. In the bottom row (top panel) equal amounts of rabbit anti-UL130 and anti-UL131 were mixed before being assayed as for the other sera. No serum was added to the wells in the right-most column (top panel). Representative micrographs were taken with a fixed exposure four days post infection.